Apogee Therapeutics, Inc. Passive Investment Disclosure (>5%)
The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group has disclosed a significant stake in Apogee Therapeutics Inc. As of 12/31/2025, Vanguard reports beneficial ownership of 2,857,824 shares of Apogee common stock, representing 5.21% of the class.
Vanguard reports no sole voting or dispositive power. It has shared voting power over 374,247 shares and shared dispositive power over 2,857,824 shares. The holdings are for clients, who have rights to dividends and sale proceeds, with no single client exceeding 5% of the class.
Vanguard states the shares were acquired and are held in the ordinary course of business, not to change or influence control of Apogee. It also notes an internal realignment effective 01/12/2026, after which certain subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies.
AI-generated analysis. How Rhea-AI works. Not financial advice.